Low-dose paclitaxel combined with thalidomide inhibits angiogenesis in mice bearing S180 sarcoma
10.3969/j.issn.1000-8179.2020.01.038
- VernacularTitle: 低剂量紫杉醇联合沙利度胺抑制小鼠 S-180 肉瘤血管生成的研究
- Author:
Nie XU
1
Author Information
1. Second Department of Oncology
- Publication Type:Journal Article
- Keywords:
Angiogenesis;
Paclitaxel;
S-180;
Thalidomide
- From:
Chinese Journal of Clinical Oncology
2020;47(1):7-11
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the effect of low-dose paclitaxel combined with thalidomide on angiogenesis in mice bearing S180 sarcoma. Methods: An S180 sarcoma-bearing mouse model was established. Forty tumor-bearing mice were randomly divided into four groups: A, the control group, administered normal saline; B, the paclitaxel group, administered 20 mg/kg paclitaxel by intraperitoneal injection three times per week for 2 weeks; C, the thalidomide group, administered 200 mg/kg thalidomide by gavage three times per week for 2 weeks; and D, the paclitaxel + thalidomide group, administered paclitaxel (20 mg/kg) and thalidomide (200 mg/kg) by intraperitoneal/intragastric administration three times per week for 2 weeks. Tumor weight, tumor inhibition rate, microvascular density (MVD), and vascular endothelial growth factor (VEGF) expression were measured. Results: Tumor weight, VEGF expression, and MVD were lower in groups B, C, and D (P<0.05) than in the control. VEGF expression and MVD were lower in group D than in groups B and C; these differences were statistically significant (P<0.05). Conclusions: Low-dose paclitaxel combined with thalidomide exerted an inhibitory effect on vascular growth in S180 sarcoma.
